The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
The addition of blinatumomab to prephase, consolidation, and after intensification in patients with B-ALL: updated results from the HOVON-146 trial
|
|
| Key learnings |
|
The primary endpoint of measurable residual disease (MRD)-negativity rate after blinatumomab consolidation was met.
|
|
In the prephase, blinatumomab led to early response rates: the CR and MRD-negativity rates were 63% and 53%, respectively. |
|
After a median follow-up of 43 months, the event-free survival (EFS) rates in patients aged ≤40 years and >40 years were 64% and 40%, respectively, and the overall survival (OS) rates were 86% and 50%, respectively. |
|
In Philadelphia-positive (Ph+) patients and Philadelphia-negative patients, the EFS rates were 75% and 64%, respectively, and the OS rates were 85% and 70%. |
|
When results were compared with the HOVON-100 trial, the addition of blinatumomab to chemotherapy improved outcomes, particularly for patients aged >40 years and Ph+ patients. |
|
Substantial toxicity was observed in patients aged >60 years; however, after chemotherapy dose adaptations there were no further safety concerns. |
|
Further studies are warranted to assess the substitution of chemotherapy for blinatumomab, particularly for Ph+ and elderly patients, to potentially reduce toxicity and improve outcomes. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
